<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Diener, Hans-Christoph</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Apixaban Associated with Reduction in Stroke and SE in Patients Unsuitable for VKA Therapy</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011-03-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">15-16</style></pages><abstract><style  face="normal" font="default" size="100%">This article discusses the results of the Apixaban Versus Acetylsalicylic Acid to Prevent Strokes [AVERROES; NCT00496769], which revealed clear evidence of a clinically important reduction in stroke and systemic embolism with apixaban over aspirin in patients with atrial fibrillation who were intolerant or otherwise considered unsuitable for vitamin K antagonist therapy.</style></abstract><number><style face="normal" font="default" size="100%">1</style></number><volume><style face="normal" font="default" size="100%">11</style></volume></record></records></xml>